Biopharma to Open One of Europe's Largest Plasma Facilities in Uzhhorod

The €75 million facility in Uzhhorod will be one of Europe's largest for blood plasma processing – and is set to open this September. Make us preferred on Google Share Facebook X (Twitter) LinkedIn Bluesky Email Copy Copied (Photo by Prime Minister Yulia Svyrydenko/Telegram) Content Share Facebook X (Twitter) LinkedIn Bluesky Email Copy Copied Flip Make us preferred on Google Ukrainian pharmaceutical and biotech company Biopharma will launch a production facility in Uzhhorod this September, with a total first-stage investment of €75 million ($80 million). The company has already invested €67 million ($71.5 million) into the project, which aims to secure Ukraine’s position in the high-tech medical sector. Construction of the plant began two years ago and is in its final stages, with the main building and raw-material warehouse already erected and equipment installed. Once completed, the facility will be one of the largest in Europe for manufacturing immunobiological drugs and processing blood plasma. Follow our coverage of the war on the @Kyivpost_official . The plant is expected to create 150 new jobs and ensure a full plasma-processing cycle within the country. According to Biopharma’s website , the company is already recruiting technical staff as it prepares to become operational this spring. The firm is also investing in local education, with plans for 25 to 30 “Bio-schools” across Ukraine, including new locations in Uzhhorod, Lviv, and Dnipro. These schools provide free, intensive training in biology, chemistry, and mathematics. “Biopharma is a prime example of a responsible Ukrainian investor continuing to build high-value manufacturing in the country even during the war,” Prime Minister Yulia Svyrydenko said on Telegram after visiting the site. Biopharma is a high-tech pharmaceutical company specializing in drugs derived from human donor plasma. Its history dates to 1896 with the founding of the Bacteriological Institute in Kyiv. Over more than a century, it evolved into a private sector leader, officially taking the name Biopharma in 2009. Other Topics of Interest Ukraine and Norway Sign Major Drone Deal Ukraine secured major military cooperation in Oslo hours after agreeing a €4 billion defense package with Germany in Berlin. According to the company’s website , in 2012, Horizon Capital and Dutch Entrepreneurial Development Bank (FMO) invested in the firm, leading to the construction of a modern research and production complex in Bila Tserkva. Later, in 2019, Biopharma sold part of its business to the German pharmaceutical giant STADA, allowing Ukrainian shareholders to focus on plasma-derived products. Biopharma currently operates 20 plasma centers across Ukraine, including a new center opened in Dnipro in early April. The company processes over 200,000 liters of plasma annually from verified donors. Its main products include: Coagulation factors that are essential for treating hemophilia. Albumins, which are used to restore blood volume after trauma or surgery. Immunoglobulins are proteins that boost the immune system. With its new capacity, Biopharma aims to fully meet Ukraine’s internal demand for blood products and expand its presence in international markets, including Europe, the Middle East, and Latin America. Mariіa Boltryk has been a journalist since 2022 and has been working for Ukraine's leading news agency Interfax-Ukraine. At Kyiv Post, she covers macroeconomics in Ukraine and business-related topics.